NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Lexaria's Patent Milestone and 2026 Shareholder Meeting
TL;DR
Lexaria's 60 global patents provide a competitive edge by securing exclusive rights to drug delivery innovations for conditions like hypertension and diabetes.
Lexaria's patent strategy involves rigorous research, animal/human testing, and international filings, resulting in 60 granted patents across key markets like the US, EU, and Australia.
Lexaria's patented drug delivery technology aims to improve global health by enhancing treatment effectiveness for conditions like epilepsy and diabetes with fewer side effects.
Lexaria's DehydraTECH platform can deliver drugs more effectively across the blood-brain barrier, potentially revolutionizing treatments for neurological conditions.
Found this article helpful?
Share it with your network and spread the knowledge!
Lexaria Bioscience Corp. has received six additional patents, increasing its total to 60 granted patents worldwide, and is reminding shareholders to vote at the upcoming 2026 Annual Meeting.
These patents strengthen Lexaria's intellectual property portfolio, provide legal recognition for its innovations in drug delivery, and enable the company to safely pursue commercial relationships in major global markets.
Family #20 (Sublingual Delivery of Nicotine) received a patent in Australia; Family #21 (Treating Hypertension) received its first EU patent; Family #24 (Treating Epilepsy) received 2 Australian and 1 EU patent; and Family #27 (Treating Diabetes) received a new US patent.
Lexaria evaluates initial hypotheses through existing scientific research, conducts animal and/or human testing to generate data, and uses this data to support patent applications in international markets before pursuing commercial relationships.
The meeting is on January 27, 2026, at 1:00 PM PT. Stockholders who held common stock at the close of business on December 1, 2025, are entitled to vote, even if they have since sold their shares.
Proxy materials are available at www.colonialstock.com/LEXX2026, where shareholders can vote by entering their control number from their proxy materials or email notice.
Lexaria's Board of Directors recommends voting FOR all proposals, and the company strongly encourages all shareholders to vote their shares on each proposal.
Lexaria now has 60 valid patents granted around most of the major potential markets worldwide, including the US, Canada, Japan, Australia, and the European Union.
Curated from NewMediaWire
